Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Phase

17 posts
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-11
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Read More

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

  • 2026-06-02
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…
BBern
New Bern intersection to undergo construction next week
Read More

New Bern intersection to undergo construction next week

  • 2026-05-16
NEW BERN, N.C. (WITN) – Construction to improve a New Bern intersection is set to begin next week.…
RRoche
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Read More

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

  • 2026-04-29
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to…
RRoche
Roche Faces Critical Week with MS Drug Data and Q1 Report
Read More

Roche Faces Critical Week with MS Drug Data and Q1 Report

  • 2026-04-09
Roche stock faces pivotal week with Phase III MS drug safety data on April 22 and Q1 sales…
RRoche
Roche Faces Critical Week with MS Drug Data and Q1 Report
Read More

Roche Faces Critical Week with MS Drug Data and Q1 Report

  • 2026-04-09
Roche stock faces pivotal week with Phase III MS drug safety data on April 22 and Q1 sales…
RRoche
Roche's Strategic Pivot Gains Momentum from Immunology and Capital Restructuring
Read More

Roche’s Strategic Pivot Gains Momentum from Immunology and Capital Restructuring

  • 2026-03-21
Roche reports strong Phase III lupus data for Gazyva and finalizes share conversion. The company also increased its…
RRoche
Roche Shares Under Pressure Following Clinical Trial Setback
Read More

Roche Shares Under Pressure Following Clinical Trial Setback

  • 2026-03-14
Roche shares drop after giredestrant fails Phase III breast cancer trial. Analysts diverge on outlook as company pivots…
RRoche
Roche's Dividend Milestone Overshadowed by Clinical Trial Setback
Read More

Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback

  • 2026-03-11
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

  • 2026-03-10
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…
RRoche
Roche's Weight-Loss Ambitions Face Reality Check
Read More

Roche’s Weight-Loss Ambitions Face Reality Check

  • 2026-03-09
Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…
RRoche
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-07
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the…
Switzerland
www.europesays.com